Brentuximab Vedotin Combination for Relapsed Diffuse Large B-Cell Lymphoma In this trial, patients with recurrent small HCC (single lesion ≤5 cm) were randomly assigned to receive either SBRT or RFA.

Personalized Chemotherapy on the Basis of Tumor Marker Decline in Poor-Prognosis Germ-Cell Tumors: Updated Analysis of the GETUG-13 Phase III Trial Earlier detection of cancer offers an opportunity to ...

Objectives To evaluate the efficacy of a new multicomponent, exercise-based injury prevention programme in football players 13–19 years old. Methods Two-arm cluster-randomised controlled trial with ...